ReDS™ is a non-invasive measurement technology for monitoring lung fluid content approved by FDA and CE. It uses electromagnetic (EM) waves propagating through the lung from chest to back and provides accurate pulmonary fluid reading – percentage of fluid in the lung. ReDS™ was validated to be equivalent to Computed Tomography (CT) lung fluid content measurements as measured by Hounsfield units with a correlation value of 0.9 . The EM waves used are safe Radio frequency (RF) low-power waves with power of 1/1000 of a cellular phone and below any threshold defined by standards and hence may be used with no limitation multiple measurements a day. The ReDS device is a mobile device which is be used in hospitals, clinics and home environments.
People who suffer from Heart Failure often accumulate fluid in their lungs, during disease exacerbation. This causes respiratory distress, which often leads to urgent ED or clinic visits that result in hospital readmissions. Current methods to monitor patients include listening with a stethoscope for noises in the lungs, or relying upon implantable devices, weight measurements and chest X-rays. A system, like ReDS™, that quickly and accurately measures lung fluids, can make a real difference for patients, caretakers, hospitals and clinics.
ReDS™ provides an accurate, actionable and absolute measurement of lung fluid content located at the right mid-lobe of the lung. The result is presented as the percentage of fluid compared to lung volume, with 20-35% representing a normal measure of fluid content. Using ReDS™ to provide guidance for a patient’s condition may lead to a significant decrease in readmissions and hospital costs.
A Vicious Cycle of Rehospitalization
Over a relatively long time (1 month), patients decompensate in mostly invisible ways with no noticeable shortness of breath or visible weight gain until just days before an acute event.
Follow Up + ReDS is a Simple Formula for Improvement
In the outpatient clinic, the patient can be evaluated with ReDS, have their medication checked, and treatment can be adjusted before discharge.
1 – Lala A, et al. “Point of Care Testing Using Remote Dielectric Sensing Reduces Heart Failure Readmission.” Journal of Cardiac Failure Vol. 24 No. 8S, August 2018, p. S52. https://www.onlinejcf.com/article/S1071-9164(18)30511-6/pdf
Sensible Medical Innovations LTD.
6 Meir Ariel St., Netanya, 4250364, Israel